Concepts (78)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Metformin | 2 | 2023 | 378 | 0.840 |
Why?
|
| CD8 Antigens | 1 | 2020 | 170 | 0.700 |
Why?
|
| Oropharyngeal Neoplasms | 3 | 2022 | 1105 | 0.610 |
Why?
|
| Dendritic Cells | 2 | 2014 | 1085 | 0.580 |
Why?
|
| Head and Neck Neoplasms | 4 | 2023 | 3976 | 0.530 |
Why?
|
| Tobacco Mosaic Virus | 1 | 2014 | 2 | 0.500 |
Why?
|
| Antigen Presentation | 1 | 2014 | 272 | 0.460 |
Why?
|
| CD40 Antigens | 1 | 2012 | 104 | 0.400 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2012 | 155 | 0.380 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2012 | 675 | 0.360 |
Why?
|
| Melanoma, Experimental | 1 | 2012 | 368 | 0.350 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2014 | 1586 | 0.350 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2012 | 1016 | 0.290 |
Why?
|
| Antigens, Neoplasm | 1 | 2012 | 1506 | 0.260 |
Why?
|
| Otorhinolaryngologic Surgical Procedures | 1 | 2021 | 60 | 0.190 |
Why?
|
| Mouth | 1 | 2021 | 122 | 0.190 |
Why?
|
| Papillomaviridae | 2 | 2022 | 624 | 0.180 |
Why?
|
| Veterans Health | 1 | 2021 | 181 | 0.180 |
Why?
|
| Risk | 2 | 2021 | 1972 | 0.170 |
Why?
|
| Lymphocyte Activation | 2 | 2014 | 1688 | 0.160 |
Why?
|
| Hypoglycemic Agents | 1 | 2021 | 586 | 0.150 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2021 | 5437 | 0.120 |
Why?
|
| Retrospective Studies | 5 | 2023 | 37905 | 0.120 |
Why?
|
| Papillomavirus Infections | 1 | 2022 | 980 | 0.110 |
Why?
|
| Mice, Inbred C57BL | 2 | 2014 | 6942 | 0.100 |
Why?
|
| Spleen | 1 | 2014 | 676 | 0.100 |
Why?
|
| Dependovirus | 1 | 2012 | 135 | 0.100 |
Why?
|
| Interleukin-12 | 1 | 2012 | 253 | 0.090 |
Why?
|
| Veterans | 1 | 2021 | 1641 | 0.090 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2016 | 1283 | 0.090 |
Why?
|
| Tumor Microenvironment | 1 | 2020 | 2864 | 0.080 |
Why?
|
| Adenoviridae | 1 | 2014 | 1459 | 0.080 |
Why?
|
| Prospective Studies | 1 | 2023 | 12873 | 0.080 |
Why?
|
| Adjuvants, Immunologic | 1 | 2012 | 657 | 0.080 |
Why?
|
| Mice | 3 | 2021 | 34495 | 0.060 |
Why?
|
| Female | 6 | 2021 | 141928 | 0.060 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2016 | 3552 | 0.060 |
Why?
|
| Immunotherapy | 2 | 2021 | 3341 | 0.060 |
Why?
|
| Lymph Nodes | 1 | 2014 | 2967 | 0.060 |
Why?
|
| Humans | 8 | 2023 | 261506 | 0.060 |
Why?
|
| Glossectomy | 1 | 2021 | 40 | 0.050 |
Why?
|
| Animals | 3 | 2021 | 59536 | 0.050 |
Why?
|
| Skin Neoplasms | 1 | 2016 | 4654 | 0.050 |
Why?
|
| Laryngectomy | 1 | 2021 | 242 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2022 | 476 | 0.040 |
Why?
|
| Lung Neoplasms | 1 | 2022 | 11538 | 0.040 |
Why?
|
| Melanoma | 1 | 2016 | 5317 | 0.040 |
Why?
|
| Middle Aged | 3 | 2021 | 86204 | 0.040 |
Why?
|
| Antineoplastic Agents | 1 | 2021 | 14289 | 0.040 |
Why?
|
| Male | 4 | 2021 | 123000 | 0.040 |
Why?
|
| Mutation | 1 | 2016 | 15179 | 0.040 |
Why?
|
| Free Tissue Flaps | 1 | 2021 | 372 | 0.040 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2021 | 2231 | 0.030 |
Why?
|
| Mutation Rate | 1 | 2016 | 223 | 0.030 |
Why?
|
| Neoplasms | 1 | 2021 | 15193 | 0.030 |
Why?
|
| Precision Medicine | 1 | 2022 | 1154 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2021 | 3981 | 0.030 |
Why?
|
| Prognosis | 2 | 2022 | 21713 | 0.030 |
Why?
|
| Receptor, ErbB-2 | 1 | 2021 | 2518 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2021 | 2403 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2016 | 1987 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2016 | 2283 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2021 | 8865 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2021 | 7222 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 6207 | 0.020 |
Why?
|
| Molecular Targeted Therapy | 1 | 2016 | 2330 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2021 | 14551 | 0.020 |
Why?
|
| Phenotype | 1 | 2016 | 6295 | 0.020 |
Why?
|
| Aged | 2 | 2021 | 70117 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2016 | 13658 | 0.010 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2016 | 4757 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2021 | 32848 | 0.010 |
Why?
|
| Young Adult | 1 | 2016 | 21445 | 0.010 |
Why?
|
| Biomarkers, Tumor | 1 | 2016 | 10331 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2016 | 29902 | 0.010 |
Why?
|
| Adolescent | 1 | 2016 | 31252 | 0.010 |
Why?
|
| Child | 1 | 2016 | 29154 | 0.010 |
Why?
|
| Adult | 1 | 2016 | 77950 | 0.010 |
Why?
|